News

The March-In Drug Price Control Narrative Crumbles While Its Damage to American Innovation Grows

Proposed ‘price’ criteria for march-in rights poses threat to U.S. innovation, critics say

Witnesses Clash Over Potential Pros and Cons of PERA in Senate IP Subcommittee Hearing

AI adds urgency to patent debate

Special council works to protect and promote STEM excellence

#27 Jamie Simpson | The U.S. policy perspective on SEPs

Apple Keeps Chasing the Ultimate Health-Tracking Watch—but It Could Take Years

The Top U.S. FRAND / RAND Licensing Developments of 2023 Part II: Ghosts of Christmas Past and Christmas Future

From AI to Amgen, Here’s Everything IP that Mattered in 2023

Gov. Hochul expected to veto N.Y. ban on noncompete agreements

Why the Apple Watch is being banned — and how Apple can avoid it

How to avoid fake products when shopping online

Scroll to Top